While tau PET appears to have high clinical utility for predicting AD symptomology among imaging biomarkers, it is possible that biomarkers of A and (N) are stronger in plasma or cerebrospinal fluid modalities. The gene discussed is MAPT; the disease is Alzheimer disease.